Skip to main content
Premium Trial:

Request an Annual Quote

Shamrock Signs Proteomics Pact with Intra-Cellular Therapies

NEW YORK, Aug. 5 (GenomeWeb News) - Shamrock Structures of Woodbridge, Ill., today announced that it has signed an agreement to provide integrated structural proteomics services to Intra-Cellular Therapies.


Under the pact, Shamrock will perform structure-activity relationship co-crystallization, synchrotron data collection, and structure determination of an Intra-Cellular Therapies protein target to which inhibitors are bound. The agreement includes an upfront fee and milestone payments. Additional terms of the deal were not disclosed.


New York-based Intra-Cellular Therapies is a privately held biopharmaceutical firm developing drugs for central nervous system disorders, such as depression, schizophrenia, Alzheimer's and Parkinson's disease.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.